Duchenne muscular dystrophy

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Live Alerts

PAN Foundation — Duchenne muscular dystrophy status changedApply now ↗

Regulatory Watchboard

10 events
May 2026DMD and Gamified Physiotherapy

Başak Çağla Arslan — NA

TrialNOT YET RECRUITING
Mar 2026A Study to Evaluate the Safety and Tolerability of Rituxan in Duchenne Muscular Dystrophy

Peking Union Medical College Hospital — NA

TrialNOT YET RECRUITING
Mar 2026Urinary Titin Biomarker in DMD

Children's Hospital of Philadelphia — NA

TrialRECRUITING
Feb 2026A Remote Study Using Technology to Assess Outcomes in DMD

University of Oxford

TrialNOT YET RECRUITING
Feb 2026Self-Efficacy Enhancement Using a Multicomponent Support Group for Caregivers of Children With DMD/SMA

Aga Khan University — NA

TrialNOT YET RECRUITING
Feb 2026The Baby Duchenne Study: Characterizing Developmental and Clinical Outcomes in the First Three Years in Children With Duchenne Muscular Dystrophy

University of Rochester

TrialNOT YET RECRUITING
Feb 2026Factors Influencing Physical Activity Levels in Children With Duchenne Muscular Dystrophy: An ICF-CY-Based Study

Hacettepe University

TrialNOT YET RECRUITING
Feb 2026Sodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne Cardiomyopathy

Larry W. Markham — PHASE1

TrialNOT YET RECRUITING
Jan 2026The Effect of Dual-tasking Program on Cognitive and Physical Functions and Independence in Activities of Daily Living in Children With Duchenne Muscular Dystrophy: A Single-blind Randomized Controlled Trial

Lokman Hekim University — NA

TrialENROLLING BY INVITATION
Jan 2026AMONDYS 45: New indication approved
FDAcompleted

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

32 programs

FINANCIAL LANDSCAPE SUMMARY

32

Total programs

24

Open now

7

Foundation grants

6

Copay cards

16

Travel grants

Foundation Grants7

NORD Patient Assistance — Duchenne muscular dystrophy

NORD Patient Assistance

OpenContact for detailsApply ↗

Good Days — Duchenne muscular dystrophy

Good Days

OpenContact for detailsApply ↗

HealthWell Foundation — Duchenne muscular dystrophy

HealthWell Foundation

OpenContact for detailsApply ↗

The Assistance Fund — Duchenne muscular dystrophy

The Assistance Fund

OpenContact for detailsApply ↗

Patient Services Inc — Duchenne muscular dystrophy

Patient Services Inc

OpenContact for detailsApply ↗

Patient Advocate Foundation — Duchenne muscular dystrophy

Patient Advocate Foundation

OpenContact for detailsApply ↗

PAN Foundation — Duchenne muscular dystrophy

PAN Foundation

ClosedContact for detailsApply ↗

Copay Assistance6

AGAMREE

Catalyst

OpenContact for detailsApply ↗

ELEVIDYS

Sarepta

OpenContact for detailsApply ↗

Deflazacort Oral Suspension

PTC

OpenContact for detailsApply ↗

Deflazacort

PTC

OpenContact for detailsApply ↗

DUVYZAT

Italfarmaco

OpenContact for detailsApply ↗

Exondys 51

Sarepta

OpenContact for detailsApply ↗

Patient Assistance Programs3

Vyondys 53

Sarepta Therapeutics, Inc.

OpenContact for detailsApply ↗

AMONDYS 45

Sarepta Therapeutics, Inc.

OpenContact for detailsApply ↗

Viltepso

NS Pharma, Inc.

OpenContact for details

Travel Grants16

Assistance Fund: Duchenne Muscular Dystrophy

The Assistance Fund

OpenContact for detailsApply ↗

Cranbury Connects Patient Assistance Programs

Contact for detailsApply ↗

Duchenne Muscular Dystrophy Copay Assistance Grant

ClosedUp to $15K/yrApply ↗

Duchenne Muscular Dystrophy Disease Fund

PAN Foundation

ClosedContact for detailsApply ↗

Duchenne Muscular Dystrophy Financial Assistance Program

The Assistance Fund

OpenContact for detailsApply ↗

Emflaza (deflazacort) Copay Assistance

OpenContact for detailsApply ↗

PAN Foundation Duchenne Muscular Dystrophy Copay Assistance

PAN Foundation

ClosedContact for detailsApply ↗

PAN Foundation Duchenne Muscular Dystrophy Copay Assistance Fund

PAN Foundation

ClosedUp to $15K/yrApply ↗

PAN Foundation Duchenne Muscular Dystrophy Copay Assistance Grant

PAN Foundation

OpenContact for detailsApply ↗

PAN Foundation Duchenne Muscular Dystrophy Disease Fund

PAN Foundation

ClosedContact for detailsApply ↗

PAN Foundation Duchenne muscular dystrophy fund

PAN Foundation

OpenContact for detailsApply ↗

QuickRx Emflaza (deflazacort) Copay Assistance

OpenContact for detailsApply ↗

SareptAssist

Contact for detailsApply ↗

The Assistance Fund (TAF) Duchenne Muscular Dystrophy Financial Assistance Program

The Assistance Fund

OpenContact for detailsApply ↗

The Assistance Fund Duchenne Muscular Dystrophy Financial Assistance Program

OpenContact for detailsApply ↗

The Assistance Fund: Duchenne Muscular Dystrophy

OpenContact for detailsApply ↗

View all support programs on disease page →

Approved Treatments

8 FDA-approved

Deflazacort Oral Suspension

(DEFLAZACORT)Orphan drug

Zydus Pharmaceuticals (USA) Inc.

FDA label ↗

ELEVIDYS

(DELANDISTROGENE MOXEPARVOVEC-ROKL)Orphan drug

Sarepta Therapeutics, Inc.

FDA label ↗

Vyondys 53

(GOLODIRSEN)Orphan drug

Sarepta Therapeutics, Inc.

FDA label ↗

AMONDYS 45

(CASIMERSEN)Orphan drug

Sarepta Therapeutics, Inc.

FDA label ↗

Viltepso

(VILTOLARSEN)Orphan drug

NS Pharma, Inc.

FDA label ↗

Deflazacort Oral Suspension

(DEFLAZACORT ORAL)Orphan drug

Sun Pharmaceutical Industries, Inc.

FDA label ↗

DUVYZAT

(GIVINOSTAT)Orphan drug

Italfarmaco SPA

FDA label ↗

AGAMREE

(VAMOROLONE)Orphan drug

Catalyst Pharmaceuticals, Inc.

FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

72 active trials
6Phase 3
3Phase 4
14Phase 2
9Phase 1
19N/A
11Unknown
5EARLY_PHASE1
3PHASE1, PHASE2
2PHASE2, PHASE3
72Total recruiting
Search clinical trials for Duchenne muscular dystrophy

Recent News & Research

6 articles
Mol Ther Nucleic AcidsJun 16, 2026

The post-pandemic pivot: mRNA therapeutics enter the chronic rare disease arena

Published in Mol Ther Nucleic Acids. Giangrande PH et al.

Read ↗
Molecular therapy : the journal of the American Society of Gene TherapyApr 9, 2026

CRISPR-Cas9-mediated upregulation of utrophin ameliorates Duchenne muscular dystrophy.

Duchenne muscular dystrophy (DMD) is a lethal neuromuscular disorder caused by loss of dystrophin. Upregulating utrophin, a dystrophin paralog, is a promising gene therapy approach. Here, we present a...

Read ↗
Current opinion in pediatricsApr 1, 2026

Treatment advances for Duchenne muscular dystrophy.

Duchenne muscular dystrophy (DMD) is a severe X-linked muscle wasting disease with childhood onset that leads to loss of ambulation in the teenage years and mortality in the second or third decade of ...

Read ↗
European journal of translational myologyMar 31, 2026

Serum biomarkers in Duchenne muscular dystrophy: a leap toward precision diagnostics.

I was interested to read the article by Dowling et al.1 in the European Journal of Translational Myology, where the authors provide a comprehensive review of serum biomarkers for Duchenne Muscular Dys...

Read ↗
GenesMar 28, 2026

Adeno-Associated Virus Toxicity in Duchenne Muscular Dystrophy: Mechanisms and Clinical Considerations.

Background/Objectives : Recombinant adeno-associated virus (AAV) vectors have revolutionized gene therapy for monogenic diseases such as Duchenne muscular dystrophy (DMD). However, high systemic doses...

Read ↗
Expert Opin Drug DiscovMar 26, 2026

The impact of antisense oligonucleotide (ASO) therapeutics on the future of rare disease drug discovery

Published in Expert Opin Drug Discov. Ruchi R et al.

Read ↗

Browse all Duchenne muscular dystrophy news →

Specialist Network

Top 6 by expertise

View all Duchenne muscular dystrophy specialists →

Quick Actions